Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AGRYLIN vs ADRIAMYCIN PFS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
Intercalation between DNA base pairs, inhibition of topoisomerase II, and generation of free radicals leading to DNA damage and apoptosis.
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
Acute lymphoblastic leukemia,Acute myeloblastic leukemia,Wilms tumor,Neuroblastoma,Soft tissue and bone sarcomas,Breast cancer,Ovarian cancer,Transitional cell bladder cancer,Thyroid cancer,Gastric cancer,Hodgkin lymphoma,Non-Hodgkin lymphoma,Multiple myeloma,Small cell lung cancer
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
60-75 mg/m² IV every 21 days as a single agent; 40-60 mg/m² IV every 21-28 days in combination regimens. Cumulative lifetime dose not to exceed 450-550 mg/m² (or 400 mg/m² with prior chest irradiation).
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Triphasic: initial α half-life 30 min (distribution), intermediate β half-life 3-4 hours (metabolism), terminal γ half-life 20-48 hours (prolonged due to extensive tissue binding and slow efflux from tissues).
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Primarily hepatic metabolism via aldo-keto reductases to doxorubicinol; also undergoes 4-O-demethylation and glucuronidation. CYP450 minimally involved.
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
Primarily hepatobiliary (∼50% as unchanged drug and metabolites in bile); renal excretion accounts for ∼5-12% over 72 hours; fecal elimination ~40%.
82–88% bound to plasma proteins (primarily albumin).
∼70% bound to plasma proteins, primarily albumin; binding is concentration-dependent and saturable at high doses.
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Extensive: 20-30 L/kg (total body water far exceeded, indicating deep tissue compartment binding, especially in liver, spleen, heart, and bone marrow).
Oral: 65–80% (median 73%)
Not bioavailable orally (0%, due to extensive first-pass metabolism and instability in GI tract); administered only intravenously.
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
No specific dose adjustment recommended for renal impairment; however, monitor for toxicity. GFR < 10 m L/min: consider dose reduction by 50% due to potential accumulation of active metabolites.
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated or reduce by 75% with extreme caution.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
30-75 mg/m² IV every 21-28 days; cumulative dose limit 400-550 mg/m². Dose based on body surface area; for infants < 1 year or BSA < 0.5 m², use weight-based dosing: 1-2 mg/kg IV every 21 days.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
No specific dose adjustment based on age alone; use with caution due to increased risk of cardiotoxicity and myelosuppression. Consider starting at lower end of dosing range (e.g., 45-60 mg/m² every 21 days) and monitor cardiac function.
None
Myocardial toxicity (including delayed congestive heart failure) may occur with cumulative doses >550 mg/m²; less if prior mediastinal irradiation. Extravasation causes severe tissue necrosis. Secondary acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) reported. Hepatic impairment requires dose adjustment. Use during pregnancy only if benefit outweighs risk.
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
Cardiotoxicity (cumulative dose-dependent, enhanced by prior chest irradiation, age >70, pre-existing cardiac disease); myelosuppression; extravasation injury; secondary malignancies; tumor lysis syndrome; hepatic impairment; radiation recall; mutagenic and carcinogenic potential; impairment of fertility.
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
Hypersensitivity to doxorubicin or any component; severe hepatic impairment; severe myelosuppression; baseline cardiac dysfunction; previous treatment with maximum cumulative doses of doxorubicin or other anthracyclines.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
Grapefruit and grapefruit juice should be avoided as they may inhibit CYP3A4 metabolism and increase doxorubicin toxicity. No other significant food interactions; maintain adequate hydration and nutrition.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
FDA Pregnancy Category D. First trimester: high risk of major congenital malformations (e.g., CNS, cardiovascular) and spontaneous abortion. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal myelosuppression. Avoid use unless maternal benefit outweighs fetal risk.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
Not recommended. Doxorubicin is excreted into human breast milk; M/P ratio not available. Potential for serious adverse reactions in nursing infants (e.g., immunosuppression, neutropenia). Discontinue breastfeeding during treatment and for at least 10 days after last dose.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
No established dose adjustments in pregnancy. Pharmacokinetic changes (increased plasma volume, altered protein binding) may require monitoring for toxicity or efficacy. Use lowest effective dose; consider dose reduction for myelosuppression or cardiotoxicity. Administration frequency may be modified based on gestational age and maternal tolerance.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
Pre-medicate with antiemetics (e.g., 5-HT3 antagonist) prior to administration. Monitor left ventricular ejection fraction (LVEF) at baseline and periodically due to cumulative dose-related cardiotoxicity (lifetime max 450-550 mg/m2, lower with prior chest radiation). Extravasation causes severe tissue necrosis; administer through a free-flowing IV line. Reduce dose in hepatic impairment (bilirubin >1.2 mg/d L). Observe for urine discoloration (red) for 1-2 days post-infusion. Avoid concurrent use with trastuzumab or other cardiotoxic agents.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
Doxorubicin may cause temporary reddish discoloration of urine for 1-2 days after treatment; this is harmless.,Report any signs of infection (fever, sore throat), unusual bleeding or bruising, mouth sores, or shortness of breath.,Your heart function will be checked before and during treatment; report any chest pain, palpitations, or swelling of ankles/feet.,This drug can cause nausea and vomiting; you will receive medications to prevent these symptoms.,Avoid pregnancy during treatment; use effective contraception. Doxorubicin can harm a fetus and may cause infertility.,Do not receive live vaccines during chemotherapy. Avoid contact with people who have recently received oral polio vaccine.,Take oral care measures (soft toothbrush, bland rinses) to prevent mouth sores.,Limit intake of grapefruit and grapefruit juice as they may affect the drug's metabolism.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AGRYLIN vs ADRIAMYCIN PFS, answered by our medical review team.
AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. ADRIAMYCIN PFS is a Anthracycline Antineoplastic that works by Intercalation between DNA base pairs, inhibition of topoisomerase II, and generation of free radicals leading to DNA damage and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AGRYLIN and ADRIAMYCIN PFS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. The standard adult dose of ADRIAMYCIN PFS is: 60-75 mg/m² IV every 21 days as a single agent; 40-60 mg/m² IV every 21-28 days in combination regimens. Cumulative lifetime dose not to exceed 450-550 mg/m² (or 400 mg/m² with prior chest irradiation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AGRYLIN and ADRIAMYCIN PFS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. ADRIAMYCIN PFS is classified as Category C. FDA Pregnancy Category D. First trimester: high risk of major congenital malformations (e.g., CNS, cardiovascular) and spontaneous abortion. Second and third trimesters: risk of fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.